AS601245

Research use only, not for human use.

A potent and selective inhibitor of JNK with IC50s of 70/220/150 nM for JNK1/2/3 respectively.

A potent and selective inhibitor of JNK with IC50s of 70/220/150 nM for JNK1/2/3 respectively; less potent for c-Src, c-Raf, p38a; exhibits in vitro and in vivo anti-inflammatory potential.(In Vitro):AS601245, an anti-Inflammatory JNK inhibitor, and Clofibrate have a synergistic effect in inducing cell responses and in affecting the gene expression profile in CaCo-2 colon cancer cells .(In Vivo):AS601245 (40, 60, and 80 mg/kg; i.p.) provides significant protection against the delayed loss of hippocampal CA1 neurons in a gerbil model of transient global ischemia.AS601245 (0.3-10 mg/kg; p.o.) is a potent inhibitor of LPS-induced TNF-α release in mice.

——

Animal Model:C3H/HEN mice Dosage:0.3, 1, 3, or 10 mg/kg Administration:P.o.Result:Decreased the TNF-α release in a dose-dependent manner.

AS-601245

MAPK/ERK Signaling

JNK

hJNK1| hJNK2| hJNK3

Neurological Disease

——

345987-15-7

372.4462

C20H16N6S

>98% (HPLC)

DMSO: ≥ 35 mg/mL

N#C/C(C1=NC(NCCC2=CC=CN=C2)=NC=C1)=C3SC4=CC=CC=C4N\3

2-Benzothiazoleacetonitrile, -[2-[[2-(3-pyridinyl)ethyl]amino]-4-pyrimidinyl]-

(-20℃)

With Ice Pack

≥ 2 years